Merck Reports Strong Q1 Earnings Boosted by Keytruda and Vaccine Sales

Merck's first-quarter earnings exceeded expectations, driven by robust sales of its Keytruda cancer drug and Gardasil vaccine, prompting an upgraded financial forecast for 2024.